Alzheimer's Association President and CEO Harry Johns said the vote was disappointing, claiming publicly released data on aducanumab justified its federal approval.
The Singapore-based company has existing plans to roll out its tRAD platform in North America and the U.K., focusing on physician groups and telerad practices.